AP3346A - Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same - Google Patents

Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Info

Publication number
AP3346A
AP3346A AP2012006191A AP2012006191A AP3346A AP 3346 A AP3346 A AP 3346A AP 2012006191 A AP2012006191 A AP 2012006191A AP 2012006191 A AP2012006191 A AP 2012006191A AP 3346 A AP3346 A AP 3346A
Authority
AP
ARIPO
Prior art keywords
same
preparing
pharmaceutical composition
composition containing
novel compounds
Prior art date
Application number
AP2012006191A
Other languages
English (en)
Other versions
AP2012006191A0 (en
Inventor
Tae Hun Kim
Eun Sil Choi
Heui Sul Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AP2012006191A0 publication Critical patent/AP2012006191A0/xx
Application granted granted Critical
Publication of AP3346A publication Critical patent/AP3346A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2012006191A 2009-10-07 2010-10-04 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same AP3346A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090095363 2009-10-07
PCT/KR2010/006760 WO2011043568A2 (en) 2009-10-07 2010-10-04 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Publications (2)

Publication Number Publication Date
AP2012006191A0 AP2012006191A0 (en) 2012-04-30
AP3346A true AP3346A (en) 2015-07-31

Family

ID=43857261

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006191A AP3346A (en) 2009-10-07 2010-10-04 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Country Status (27)

Country Link
US (1) US8729273B2 (tr)
EP (1) EP2467378B1 (tr)
JP (1) JP5702392B2 (tr)
KR (1) KR101751325B1 (tr)
CN (1) CN102574839B (tr)
AP (1) AP3346A (tr)
AR (1) AR078504A1 (tr)
AU (1) AU2010304091B2 (tr)
BR (1) BR112012007828B8 (tr)
CA (1) CA2774133C (tr)
CL (1) CL2012000738A1 (tr)
CO (1) CO6430501A2 (tr)
EA (1) EA021025B1 (tr)
EC (1) ECSP12011793A (tr)
ES (1) ES2599829T3 (tr)
HK (1) HK1170224A1 (tr)
IL (1) IL218669A (tr)
MA (1) MA33880B1 (tr)
MX (1) MX2012003782A (tr)
MY (1) MY162813A (tr)
PE (1) PE20121088A1 (tr)
SG (1) SG179186A1 (tr)
TR (1) TR201203989T1 (tr)
TW (1) TWI423962B (tr)
UA (1) UA110197C2 (tr)
WO (1) WO2011043568A2 (tr)
ZA (1) ZA201202544B (tr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
EP3243515B1 (en) * 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY176149A (en) 2013-03-29 2020-07-24 Teijin Pharma Ltd Pyrazole derivative
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
CN104774172B (zh) * 2015-04-08 2017-03-22 河南师范大学 一种3‑氰基吲哚类化合物的合成方法
AU2016316278B2 (en) * 2015-09-02 2020-06-04 Sunshine Lake Pharma Co., Ltd. Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
CN110612286A (zh) * 2017-02-28 2019-12-24 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
IL276783B2 (en) * 2018-06-01 2023-12-01 Autophagysciences Inc The composition and pharmaceutical compound containing it
CN111072647B (zh) * 2019-12-11 2021-02-26 沈阳药科大学 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
TW202336015A (zh) * 2020-11-04 2023-09-16 南韓商Ｌｇ化學股份有限公司 唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物
AU2021392532A1 (en) 2020-12-01 2023-06-29 Lg Chem, Ltd. Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same
CN116528852A (zh) 2020-12-01 2023-08-01 株式会社Lg 化学 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途
MX2023011500A (es) * 2021-04-16 2023-10-04 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico.
CN117242062A (zh) * 2021-04-27 2023-12-15 株式会社Lg化学 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法
CN117203200A (zh) * 2021-04-27 2023-12-08 株式会社Lg化学 黄嘌呤氧化酶抑制剂的制备方法
WO2022231263A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
KR20240005050A (ko) * 2021-04-29 2024-01-11 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 크산틴 옥시다아제 억제제
CN117412746A (zh) * 2021-06-15 2024-01-16 株式会社Lg化学 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物
AR126164A1 (es) 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
TWI822151B (zh) 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
KR20230006408A (ko) 2021-07-02 2023-01-10 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
WO2023208103A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于痛风的化合物
CN116715633A (zh) * 2022-04-27 2023-09-08 江苏新元素医药科技有限公司 可用于降尿酸的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2008126898A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. （アザ）インドール誘導体及びその医薬用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU218942B (hu) 1990-11-30 2001-01-29 Teijin Ltd. 2-Fenil-tiazol-származékok, az ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
AU2001270260A1 (en) * 2000-06-30 2002-01-14 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
JP2004502768A (ja) * 2000-07-10 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー 置換インドールオキソアセチックピペラジン誘導体の組成物と抗ウイルス活性
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
WO2004014354A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
KR20080035594A (ko) * 2005-07-01 2008-04-23 닛뽕 케미파 가부시키가이샤 크산틴옥시다아제 저해제
RU2008118156A (ru) 2005-10-07 2009-11-20 Астеллас Фарма Инк. (Jp) Производное триарилкарбоновой кислоты
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
JP5378988B2 (ja) 2007-04-11 2013-12-25 キッセイ薬品工業株式会社 ５員環へテロ環誘導体及びその医薬用途
US20110201815A1 (en) * 2008-10-15 2011-08-18 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative and use thereof for medical purposes
CA2740766C (en) 2008-10-16 2016-02-02 Automatic Bar Controls, Inc. Apparatus and method and turntable for on-demand distributing of a food product
JP5529876B2 (ja) * 2008-10-17 2014-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物
CN102574788A (zh) * 2009-09-24 2012-07-11 弗·哈夫曼-拉罗切有限公司 作为crac调节剂的吲哚衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2008126898A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. （アザ）インドール誘導体及びその医薬用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KELVIN BILLINGSLEY ET AL: "Highly Efficient Monophosphine-Based Catalyst for the Palladium-Catalyzed Suzuki-Miyaura Reaction of Heteroaryl Halides and Heteroaryl Boronic Acids and Esters", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 11, 1 March 2007 (2007-03-01), pages 3358 - 3366, XP055056735 *

Also Published As

Publication number Publication date
CA2774133A1 (en) 2011-04-14
US8729273B2 (en) 2014-05-20
CN102574839B (zh) 2015-11-25
EA201270520A1 (ru) 2012-10-30
BR112012007828B8 (pt) 2021-05-25
AU2010304091B2 (en) 2016-06-09
ECSP12011793A (es) 2012-05-30
PE20121088A1 (es) 2012-08-17
KR20110037883A (ko) 2011-04-13
ES2599829T3 (es) 2017-02-03
WO2011043568A3 (en) 2011-09-29
KR101751325B1 (ko) 2017-06-27
HK1170224A1 (zh) 2013-02-22
WO2011043568A2 (en) 2011-04-14
SG179186A1 (en) 2012-05-30
CL2012000738A1 (es) 2012-09-14
IL218669A (en) 2016-08-31
UA110197C2 (ru) 2015-12-10
TWI423962B (zh) 2014-01-21
EA021025B1 (ru) 2015-03-31
ZA201202544B (en) 2012-12-29
AR078504A1 (es) 2011-11-09
CN102574839A (zh) 2012-07-11
AU2010304091A1 (en) 2012-04-19
TR201203989T1 (tr) 2012-09-21
JP2013507355A (ja) 2013-03-04
MY162813A (en) 2017-07-31
IL218669A0 (en) 2012-05-31
MA33880B1 (fr) 2013-01-02
EP2467378A4 (en) 2013-04-24
EP2467378B1 (en) 2016-07-27
AP2012006191A0 (en) 2012-04-30
JP5702392B2 (ja) 2015-04-15
US20120184582A1 (en) 2012-07-19
TW201118077A (en) 2011-06-01
CO6430501A2 (es) 2012-04-30
MX2012003782A (es) 2012-08-31
BR112012007828B1 (pt) 2021-01-12
EP2467378A2 (en) 2012-06-27
BR112012007828A2 (pt) 2016-03-08
CA2774133C (en) 2019-06-25

Similar Documents

Publication Publication Date Title
AP3346A (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
HK1219419A1 (zh) 作為 抑制劑的亞氨基噻二嗪二氧化物化合物、組合物及其用途
HK1182098A1 (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) -(bace) 56--2h-[14]-3--
EP2464626A4 (en) PROCESSES, COMPOUNDS AND COMPOSITIONS FOR THE EXPORTS OF 1,3-PROPANE-SULFONIC ACID
ZA201208198B (en) Picolinamide and pyrimidine-4-carboxamine compounds, process for preparing and pharmaceutical composition comprising the same
WO2010093191A3 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
EP2485591A4 (en) IMINOTHIADIAZINOXIN COMPOUNDS AS BACE HEMMER, COMPOSITIONS AND ITS USE
ZA201203183B (en) Sulfomethylsuccinates, process for making same and compositions containing same
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
MY144726A (en) Diosmetin compounds, process for their preparation and pharmaceutical compositions containing them
IL216388A0 (en) New compounds, pharmaceutical composition and methods relating thereto
HK1165798A1 (zh) 取代的吡咯衍生物、含這些衍生物的藥用組合物以及用其治療帕金森氏病的方法
EP2439198A4 (en) NOVEL PROCESS FOR PREPARING ROSUVASTATIN, INTERMEDIATE COMPOUNDS USEFUL FOR PREPARING ROSUVASTATIN, AND CORRESPONDING PREPARATION METHOD
ZA201103444B (en) Heteroaromatic compounds for use as hif inhibitors
IL207183A (en) Dihydroindolone compounds, a process for their preparation and their pharmaceutical compositions
EP2394993A4 (en) A NEW 2,6-SUBSTITUTED 3-NITROPYRIDINE DERIVATIVE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
EP2285215A4 (en) NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREFOR AND METHOD OF USE THEREOF
GB0800570D0 (en) Composition, process for preparation and method of use
IL203064B (en) A pharmaceutical preparation containing compound 11 - deoxy - prostaglandin and a method for stabilizing the compound
IL220621A (en) History of Naphthalene-1, 4-Diane, Pharmaceutical Preparations and Kit Containing Them for Use as Anticoagulants
IL212850A0 (en) Novel method for the preparation of granulates of active constituents, and granulates as obtained
AP2012006352A0 (en) AzabicycloÄ3.1.0Ühex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same.
EP2366684A4 (en) NOVEL COMPOUND OF THE PTÉROCARPAQUINONES FAMILY, PROCESS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THESE NOVEL COMPOUNDS OF THE PTÉROCARPAQUINONES FAMILY, USES AND THERAPEUTIC METHOD
HK1153195A1 (en) Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it